This week’s MoneyShow column on Forbes.com entitled, “Heart-Felt Buys: 6 Cardiac Opportunities,” highlights top advisors’ favorite stocks among cardiac treatments and heart device makers. Mike Cintolo, Chief Analyst of Cabot Top Ten Trader, and Tyler Laundon, Chief Analyst of Cabot Small-Cap-Cap Confidential are featured.
Mike is following iRhythm Technologies (IRTC), a small firm with a potentially revolutionary product. The company’s Zio technology is a wearable patch heart monitor that can give up to two weeks of electrocardiogram (ECG) data on cardiac arrhythmias like atrial fibrillation. Mike said, “Growth remains amazing—second-quarter revenues soared 52% (topping expectations), and the firm broke even on cash flow for the first time ever—and with FDA clearance for a next-generation product, iRhythm’s business should continue to soar for a long time to come.”
Tyler likes LeMaitre Vascular (LMAT), which develops and sells a wide variety of medical devices for treating peripheral vascular disease. According to Tyler, “The company went public in 2006, has a market cap of $535 million, and its growth stock is about as steady as you’ll find in the healthcare industry.”